Consensus Synthesis: OSUR Proxy Contest

Altai Capital Management vs. OraSure Technologies Board & Management

---

Consensus Summary

This proxy contest reflects a textbook activist engagement against a company with demonstrable long-term underperformance, meaningful governance deficiencies, and contested capital allocation decisions. OraSure's stock has declined 67% over five years and 56% over ten years, revenue has collapsed from $387M to $115M (largely but not entirely attributable to COVID-era normalization), and cash has eroded by ~$90M since end-of-2023 — all while management committed $55M+ to two pre-revenue, early-stage companies with unmet commercial expectations.

The contest was resolved via a Cooperation Agreement (April 16, 2026) before the Annual Meeting, resulting in: (1) appointment of Altai nominee John Bertrand to the Board, (2) a board declassification commitment, (3) formalized engagement/information-sharing mechanisms, and (4) standstill provisions limiting Altai's agitation through the 2026 Annual Meeting. This settlement materially addressed the most legitimate elements of Altai's agenda while preserving management's ability to execute on pending FDA catalysts.

All four models agree that Altai's financial critique is substantially correct and that the settlement outcome (Bertrand appointment + declassification) is a net positive for shareholders. The primary divergence is whether institutional investors should continue to lean activist or give management space to execute under the new governance framework.

---

Model Comparison

---

Points of Agreement

All four models converge on the following conclusions with high consistency:

1. Altai's Financial Critique is Substantially Correct
Every model acknowledges that OraSure's multi-year underperformance is severe, documented, and difficult to defend. The 67%/56% stock decline over 5/10 years, the ~$90M cash burn, 30% manufacturing utilization, and the 27% decline in non-COVID revenue in the same year Sapphiros was projected to "accelerate revenue growth" represent a factually strong case that transcends narrative framing. No model disputes the core metrics.

2. Capital Allocation Record is Problematic
Universal agreement that the Sapphiros investment thesis was explicitly not met, and that the potential Aspinall/Sherlock conflict of interest represents a genuine governance gap that management did not adequately address. The combined $55M+ committed to pre-revenue assets against a $218M market cap is flagged by all models as a concentrated and poorly justified bet.

3. John Bertrand's Appointment is a Clear Positive
All models view Bertrand as a credible, domain-relevant addition to the Board. His Digital Diagnostics background (FDA-cleared autonomous AI diagnostic solution) is directly applicable to OraSure's business context, distinguishing him sharply from the more financially-oriented Bajaj. All models implicitly or explicitly endorse the settlement's outcome of Bertrand-in, Bajaj-out.

4. Board Declassification is an Unambiguous Governance Improvement
All models agree that the classified board structure was an unjustifiable entrenchment mechanism and that the commitment to seek shareholder approval for declassification is a meaningful governance win, regardless of whether it was Altai-induced or preexisting.

5. Rishi Bajaj's Exclusion is Appropriate
Three of four models (Claude, Gemini, and implicitly Grok through support of the settlement) agree that Bajaj's track record — particularly the ContextLogic "liquidation-style outcome" and the Digimarc -65% performance since appointment — makes his exclusion from the settled board a reasonable outcome. His primary value-add appeared to be pressure for a forced sale rather than operational contribution.

6. Management's Compensation Structure is Difficult to Defend
All models flag the ~75% increase in board stock-based awards during a year of severe underperformance, and the CEO compensation structure where time-vested equity is arguably conflated with performance-linked pay, as legitimate and unresolved concerns.

---

Points of Divergence

1. Overall Recommendation: The Central Divide

The sharpest disagreement is between models recommending continued activist alignment (Grok, OpenAI) versus supporting the settlement framework as a management validation (Gemini) or a nuanced middle path (Claude).

• Grok and OpenAI argue that the activist's case is strong enough to warrant ongoing institutional alignment with Altai's perspective, emphasizing that the concessions extracted (Bertrand + declassification) validate the activist thesis and that further pressure may be warranted given the financial trajectory.
• Gemini argues that the concessions made are sufficient to warrant giving management space to execute, particularly given upcoming FDA catalysts, and that destabilizing management further during a critical commercial period is counterproductive.
• Claude occupies the middle ground: supporting the settlement as the optimal current outcome while establishing explicit milestone triggers that would warrant re-engagement with activist pressure (cash below $150M, FDA clearances not received, non-COVID revenue not stabilizing by mid-2027).

This divergence is principled rather than arbitrary: it reflects a genuine analytical difference about whether the settlement "fixed" the problem sufficiently or merely introduced a check on ongoing mismanagement.

2. Altai's Own Credibility

Gemini and Claude give meaningful weight to Altai's credibility gap — specifically, the inconsistency of selling 127,000 shares at $2.98 while claiming intrinsic value of $4.54–$6.60. Grok and OpenAI largely discount this as routine portfolio management and do not penalize Altai's argument materially for this inconsistency.

3. Management's Strategic Vision — Deserves Benefit of the Doubt?

Claude and Gemini give more credit to management's near-term FDA catalyst narrative (CT/NG self-test and Colli-Pee targeting a $2B market) as a legitimate reason to avoid forcing a sale at the trough of the operating cycle. Grok and OpenAI are more skeptical, citing OraSure's history of missed forward projections (Sapphiros) as a reason to discount management's execution credibility on new promises.

4. Forced Sale Timing

Grok and OpenAI are more sympathetic to Altai's sum-of-the-parts sale thesis ($4.54–$6.60/share). Claude and Gemini note that forcing a sale now — before FDA regulatory de-risking — could crystallize value at a discount, making the "wait 12-18 months" argument from management strategically sound, even if credibility-constrained.

---

Consensus Recommendation

Support Settlement Outcome / Monitor for Re-Engagement

Strength: Moderate

The models are 3-1 in favor of activist-leaning positions (Grok: Support Activist; OpenAI: Support Activist; Claude: Support Settlement with activist-aligned monitoring triggers; Gemini: Support Management), but the nature of that support is more nuanced than a clean activist vote. Given that the proxy contest was resolved pre-vote via the Cooperation Agreement, the actionable consensus recommendation for institutional investors is:

1. Endorse the Cooperation Agreement outcome as negotiated. Bertrand's appointment and board declassification are genuine improvements that address the most structurally important elements of Altai's agenda without the disruption of a contested vote during a critical regulatory period.

2. Maintain activist-aligned monitoring posture. The settlement does not resolve the underlying concerns about management execution credibility, capital allocation discipline, or compensation alignment. Institutional investors should establish explicit watch points:

   • FDA clearance decisions on CT/NG self-test and Colli-Pee (expected 2026)
   • Operating cash flow breakeven achievement (management's stated 2026 target for cash flow neutrality)
   • Non-COVID revenue stabilization — the core business must demonstrably stop declining
   • Cash balance: deterioration below ~$150M should trigger a formal strategic review demand
   • Any further increases in director/executive compensation without corresponding performance improvement

3. If milestones are unmet by mid-2027, support a formal strategic review process. The financial case for a sale at that point — including potential synergies available to a strategic buyer that cannot be self-realized — would be compelling and difficult to oppose.

The recommendation is moderate rather than strong because: (a) the contest was resolved pre-vote, removing the need for a clean ballot choice; (b) the models are genuinely split between "the settlement is sufficient" and "the underlying problems remain unresolved"; and (c) the binary nature of upcoming FDA outcomes creates meaningful uncertainty in either direction.

---

Confidence Score

Confidence: 7/10

Rationale:

• High confidence (9/10) that Altai's financial critique is correct, that the settlement outcome (Bertrand + declassification) is superior to a pure management victory, and that governance concerns remain insufficiently resolved.
• Moderate confidence (6/10) in the timing dimension — the FDA catalyst argument is inherently speculative, and OraSure's demonstrated pattern of unmet forward projections creates meaningful execution risk on the 2026-2027 commercial narrative.
• Uncertainty discount applied for: (a) binary FDA regulatory outcomes that could materially alter the strategic calculus; (b) unknown details of the Aspinall/Sherlock conflict that could change the governance severity assessment; (c) Bertrand's actual influence on the board post-settlement, which will only be observable over time; and (d) broader diagnostics M&A market conditions affecting any potential sale price realization.

The 1-point spread across three of four models (7/10, 8/10, 8/10, 7/10) reflects genuine analytical alignment on the facts with principled disagreement on the forward-looking recommendation — an appropriate reflection of the inherent uncertainty in proxy contest outcomes.